Table 3 Histoclinical comparison of the two basal subgroups defined with the immune metagene in the independent validation series

Age (372)

0.71*

≤ 50 years

53 (62%)

169 (59%)

1

> 50 years

33 (38%)

117 (41%)

1.11 (0.66-1.89)

Pathological tumor size, pT (394)

0.11*

pT1

32 (33%)

73 (24%)

1

pT2-4

64 (67%)

225 (76%)

1.54 (0.9-2.6)

Pathological lymph node status, pN (420)

0.90*

negative

62 (65%)

208 (64%)

1

positive

33 (35%)

117 (36%)

1.06 (0.64-1.77)

Tumor grade (420)

ND

SBR 1

0 (0%)

13 (4%)

SBR 2-3

103 (100%)

304 (96%)

IHC ER status (434)

0.57*

negative

73 (77%)

269 (79%)

1

positive

22 (23%)

70 (21%)

0.86 (0.49-1.57)

Lymphocyte infiltrate (56)

0.51*

absent

6 (46%)

14 (33%)

1

present

7 (54%)

29 (67%)

1.76 (0.41-7.48)

Adjuvant chemotherapy (354)

0.43*

no

49 (64%)

162 (58%)

1

yes

28 (36%)

115 (42%)

1.24 (0.72-2.18)

Adjuvant hormone therapy (269)

0.11*

no

59 (91%)

197 (97%)

1

yes

6 (9%)

7 (3%)

0.40 (0.12-1.46)

Follow-up (months, median) (380)

95

89

0.44**

Relapses (380)

25 (26.3%)

133 (46.7%)

4.77 E-04*

0.41 (0.23-0.70)

5-year DFS (380)

78%

54%

1.6 E-04***